Pharmaceutical giant Mylan (MYL) was the worst performing stock in the S&P 500 on Monday, making it TheStreet's Move of the Day. Shares gave up about 14.5 percent after Israel-based Teva Pharmaceuticals (TEVA) withdrew its offer to acquire Canonsburg, PA-based Mylan, a deal previously announced back in April. Instead, Teva will acquire the generics division of Dublin-based Allergan PLC (AGN) in a merger worth $40.5 billion. Allergan shares rallied 5.4 percent. The transaction will net Allergen $33.75 billion in cash, along with Teva shares worth $6.75 billion. Teva expects the merger to close during first quarter of next year. Shares of Mylan fell about 26 percent since their high back on April 24. TheStreet's Scott Gamm reports from New York.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.